Engineered Nonviral Nanocarriers for Intracellular Gene Delivery Applications

Purpose: Viral vectors give high gene-transfer efficiency but carry risks of immunogenicity, oncogenic transformation, limited cargo capacity, and manufacturing difficulty. Nonviral nanocarriers are safer and cheaper alternatives, but they still suffer from low transfection efficiency because of extracellular and intracellular barriers. This review addresses the need to comparatively understand lipid, polymer, and inorganic material platforms and their design rules for efficient intracellular nucleic acid delivery. ---

Hypothesis: The review’s central thesis is: if nonviral nanocarrier material platforms—lipids, polymers, and inorganic nanoparticles—are rationally designed and surface-engineered to protect nucleic acids, promote cellular uptake, facilitate endosomal escape, and enable targeting, then they can achieve efficient intracellular gene delivery with lower immunogenicity and toxicity than viral vectors. ---

Aims: - Compare the major material platforms for nonviral gene delivery: lipid, polymer, and inorganic nanocarriers. - Discuss mechanisms of nanocarrier–cell interaction, binding, uptake, and intracellular trafficking. - Outline design considerations for nucleic acid protection, cellular internalization, endosomal escape, and cargo release. - Review targeting strategies, including passive (EPR) and active ligand/receptor-based targeting. - Highlight recent advances and remaining challenges for clinical translation. ---

Delivery system: Payloads: Plasmid DNA (pDNA), siRNA, antisense oligonucleotides, mRNA, other nucleic acids. Lipid platforms: - Liposomes, lipoplexes, lipopolyplexes. - Cationic lipids: DOTMA, DOTAP, DC-Chol, DOPE, DOTAU, synthetic lipidoids. - Examples: Lipofectin, solid lipid nanoparticles, cationic solid lipid nanoparticles for paclitaxel/siRNA co-delivery. Polymer platforms: - PEI: linear and branched; high charge density, proton sponge effect, but cytotoxicity. - PLGA: FDA-approved, biodegradable, controlled release. - Dendrimers: PAMAM, PPI, PLL-based dendrons. - Chitosan: natural, low toxicity, biodegradable, amine-rich. - Alginate nanogels: Ca-alginate, often combined with PEI, PLL, or chitosan. Inorganic platforms: - Gold nanoparticles (AuNPs): thiol–Au conjugation, layer-by-layer assembly, photothermal/imaging capabilities. - Carbon nanotubes (CNTs): amine-functionalized, siRNA conjugation via disulfide bonds. - Quantum dots (QDs): semiconductor nanocrystals, imaging plus gene delivery. - Magnetic nanoparticles: iron oxide, MRI tracking, magnetic guidance. - Mesoporous silica nanoparticles (MSNPs): high pore volume, PAMAM/PEI capping. - Calcium phosphate nanoparticles: biocompatible, pH-sensitive dissolution. Targeting ligands: Antibodies, aptamers, cell-penetrating peptides (HIV-TAT, VP22), NLS peptides, transferrin, RGD, PLL, arginine-rich peptides, tumor-homing peptides. ---

Approach: Narrative review of published literature. No primary experimental groups. Model systems discussed include: - In vitro: HeLa, COS-7, HUH-7, CHO, 293T, lung cancer cells, endothelial cells, neuronal cells, primary cardiomyocytes, human T cells, ovarian cancer cells. - In vivo: Mouse models for cancer, liver, lung, spleen, kidney, and neuronal tissues; tail-vein injection, implantation, magnetic guidance. - Disease context: Cancer therapy, tissue engineering, regenerative medicine, monogenic and cardiovascular diseases, neurodegenerative diseases. ---

Key methods: Techniques and endpoints highlighted across cited studies: - Transfection efficiency (reporter gene expression, luciferase, GFP, β-galactosidase). - Gene silencing/knockdown (siRNA, antisense ODN). - Fluorescence/confocal microscopy for cellular uptake and intracellular trafficking. - MRI and near-infrared fluorescence imaging for magnetic nanoparticle tracking. - Dynamic light scattering and electron microscopy for size/morphology. - Cytotoxicity and biocompatibility assays. - Serum stability and nuclease protection assays. - Biodistribution studies. - Endocytosis inhibition and pathway analysis. ---

Key results: - Lipidoid library: >1,200 lipid-like materials screened; achieved siRNA silencing comparable to Lipofectamine 2000 in vitro and in mouse/rat liver in vivo. - Gold–PEI nanoparticles: transfection efficiency ~12-fold more potent than PEI alone in COS-7 cells; quaternary ammonium AuNPs ~8-fold more effective than PEI in 293T cells. - Chitosan/siRNA: knockdown up to 90% in a papillary thyroid carcinoma model. - Carbon nanotube–siRNA: 60–70% knockdown in human T cells and primary cells; CNT–pDNA β-galactosidase expression 5–10-fold higher than naked pDNA. - Magnetic dendrimer–siRNA: EGFR protein reduced by 70–80% in human glioblastoma cells. - Calcium phosphate: optimized protocols achieved up to 60% transfection in low-density primary neuronal cultures. - Passive targeting: nanoparticles <500 nm can exploit EPR effect for tumor accumulation, though EPR is variable across tumors and patients. - Serum effect: serum proteins inhibit transfection by neutralizing cationic carriers. ---

Interpretation: The authors conclude that nonviral nanocarriers are promising alternatives to viral vectors, but no single ideal platform exists for all applications. Rational design requires deep understanding of vector–nucleic acid interactions, cellular uptake pathways, endosomal escape, and targeting. Significant progress has been made, but much work remains before any nanocarrier becomes a viable clinical option for human gene therapy. ---

Limitations: - Low transfection efficiency of nonviral systems compared with viral vectors. - Extracellular and intracellular barriers: nuclease degradation, poor cellular uptake, endosomal trapping, nuclear delivery. - Cytotoxicity: high-molecular-weight PEI and cationic lipids can be toxic. - Serum inhibition: serum proteins reduce transfection efficiency. - Stability issues: electrostatic complexes may be unstable and require fresh preparation. - Targeting limitations: passive EPR effect is variable and not universal; active targeting requires specific ligands and may be masked by protein corona. - Clinical translation challenges: safety concerns from past gene therapy trials, scale-up, manufacturing, and regulatory hurdles. - Material-specific limitations: carbon nanotube toxicity remains controversial; calcium phosphate size control is difficult; magnetic nanoparticle stability in physiological solutions is challenging. - As a review: Not a systematic review or meta-analysis; no primary data. This response is AI-generated, for reference only.